Cytek Biosciences, Inc. Common Stock CTKB
$4.89
+2.30%
at last close
Analyst Consensus
- Consensus Rating
- Buy (3 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $5.69
- Implied Upside
- +16.3%
- Price Target Range
- $4.75 – $7.50
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-13 | Stephens & Co.Mason Carrico |
Maintains | Overweight | $6 → $5 |
| 2026-05-12 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $6 → $6 |
| 2026-01-08 | TD CowenBrendan Smith |
Maintains | Buy | $4 → $5 |
| 2025-11-11 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $8 → $8 |
| 2025-05-28 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $9 → $7 |
| 2025-05-12 | Goldman SachsMatthew Sykes |
Maintains | Sell | $4 → $3 |
| 2025-03-19 | Stephens & Co.Mason Carrico |
Reiterates | Overweight | $6 |
| 2025-03-04 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $9 → $8 |
| 2024-11-11 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $8 → $9 |
| 2024-08-13 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $9 → $8 |
| 2024-05-13 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $10 → $9 |
| 2024-03-06 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $11 → $10 |
| 2024-02-29 | Goldman SachsMatthew Sykes |
Maintains | Buy | $9 → $10 |
| 2023-12-14 | Stephens & Co.Mason Carrico |
Initiates coverage on | Overweight | $9 |
| 2023-11-09 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $8 → $7 |
| 2023-10-24 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $13 → $8 |
| 2023-10-16 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $15 → $10 |
| 2023-07-19 | Raymond JamesAndrew Cooper |
Initiates coverage on | Market perform | — |
| 2023-05-11 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $14 → $13 |
| 2023-05-10 | Goldman SachsMatthew Sykes |
Maintains | Buy | $14 → $12 |
| 2023-03-07 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $18 → $15 |
| 2023-03-02 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $15 → $14 |
| 2023-03-02 | Goldman SachsMatthew Sykes |
Maintains | Buy | $16 → $14 |
| 2022-08-18 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $12 → $16 |
| 2022-08-12 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $11 → $15 |
| 2022-08-11 | Goldman SachsMatthew Sykes |
Maintains | Buy | $15 → $17 |
| 2022-07-14 | Goldman SachsMatthew Sykes |
Maintains | Buy | $12 → $15 |
| 2022-05-16 | Piper SandlerDavid Westenberg |
Maintains | Overweight | $17 → $12 |
| 2022-05-13 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $18 → $11 |
| 2022-05-12 | Goldman SachsMatthew Sykes |
Maintains | Buy | $14 → $12 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $4.89
- Market Cap
- $621.32 million
- 52-Week Range
- $3.09 – $6.18
- Average Volume
- 838K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.